1. m-TOR inhibitors in the current practice;Alalawi;J. Clin. Exp. Nephrol.,2017
2. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study;Asahina;Invest. N. Drugs,2013
3. Evolving role for pharmacotherapy in NAFLD/NASH;Attia;Clin. Transl. Sci.,2021
4. Rapamycin and mTOR kinase inhibitors;Ballou;J. Chem. Biol.,2008
5. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors;Banerji;J. Clin. Oncol.,2012